

CURRICULUM VITAE

Name: Carol A. Sherman, M.D.

Office Address: Hollings Cancer Center
Room 116B
Medical University of South Carolina
86 Jonathan Lucas Street
P.O. Box 250955
Charleston, South Carolina 29425

Citizenship: USA

Education:

Institution/Location	Years	Degree/Date	Field of Study
American International College Springfield, Massachusetts	1976 - 1980	B.A. 5/25/80 With Highest Honor	Chemistry & Biochemistry
University of Massachusetts Medical School Worcester, Massachusetts	1980 - 1984	M.D. 6/3/84	Medicine

Internship:

Internal Medicine Internship	University of Massachusetts Medical Center	7/1/84 - 6/30/85
------------------------------	---	------------------

Residencies:

Internal Medicine Residency	University of Massachusetts Medical Center	7/1/85 - 6/30/87
Hematology/Oncology Fellowship	University of Massachusetts Medical Center	7/1/87 - 6/30/89

Specialty/Board Certifications:

Date:

National Board of Medical Examiners	7/1/85
-------------------------------------	--------

American Board of Internal Medicine	9/6/87
Subspecialty Board of Medical Oncology	11/7/89

Licensure:

Date:

State of Massachusetts # 55907	5/28/86 - 12/16/97
State of New Hampshire # 8072	5/10/89 - 6/30/96
State of South Carolina # 19577	8/25/97 - Current

Faculty Appointments:

<u>Years:</u>	<u>Rank:</u>	<u>Institution:</u>	<u>Dept:</u>
1989 - 1997	Assistant Professor	University of Massachusetts Medical School	Medicine
1997 - 2002	Assistant Professor	Medical University of South Carolina	Medicine
2002 - Present	Associate Professor	Medical University of South Carolina	Medicine

Administrative Appointments:

<u>Years:</u>	<u>Position:</u>	<u>Institution:</u>	<u>Dept:</u>
1996 - 1997	Associate Director Lung Cancer Clinic	University of Massachusetts Medical Center	Medicine
1996 - 1997	Physician Director Ambulatory Oncology	University of Massachusetts Medical Center	Medicine
1996 - 1997	Physician Director Cancer Services	Wing Memorial Hospital Palmer, Massachusetts	Medicine
1997 - 1998	Compliance Officer	Medical University of South Carolina	Medicine
1998 - 2001	Associate Medical Director Oncology Inpatient Service	Medical University of South Carolina	Medicine
1998 - Present	Medical Director Hollings Cancer Center	Medical University of South Carolina	Cancer Center

2004 - 2007	Interim Chief Division of Hematology / Oncology	Medical University of South Carolina	Medicine
2007 - Present	Associate Chief for Clinical Affairs, Division of Hematology/Oncology	Medical University of South Carolina	Medicine

Hospital Appointments/Privileges:

1989 - 1990	Courtesy Staff Hematologist, Worcester City Hospital, Worcester, Massachusetts
1989 - 1990	Consulting Staff Hematologist/Oncologist Wing Memorial Hospital, Palmer, Massachusetts
1989 - 1996	Courtesy Staff Hematologist/Oncologist, Monadnock Community Hospital, Peterborough, New Hampshire
1989 - 1996	Staff Hematologist/Oncologist, Medical Center of Central Massachusetts, Worcester, Massachusetts
1989 - 1996	Associate Staff Hematologist/Oncologist, University of Massachusetts Medical Center, Worcester, Massachusetts
1989 - 1997	Consulting Staff Hematologist/Oncologist, Athol Memorial Hospital, Athol, Massachusetts
1990 - 1997	Courtesy Staff Hematologist/Oncologist, Wing Memorial Hospital, Palmer, Massachusetts
1992 - 1996	Courtesy Staff Hematologist/Oncologist, Leominster Hospital, Leominster, Massachusetts
1994 - 1996	Courtesy Staff Hematologist/Oncologist, Mary Lane Hospital, Ware, Massachusetts
1996 - 1997	Courtesy Staff Hematologist/Oncologist, Memorial Health Care (formerly Medical Center of Central Massachusetts), Worcester, Massachusetts
1996 - 1997	Staff Hematologist/Oncologist, University of Massachusetts Medical Center, Worcester, Massachusetts
1997 - Present	Staff Oncologist, Medical University of South Carolina, Charleston, South Carolina

1997 - Present Consulting Staff Hematologist/Oncologist, Ralph H. Johnson Medical Center, Charleston, South Carolina

1998 - 2001 Courtesy Staff Oncologist, East Cooper Regional Medical Center, Mount Pleasant, South Carolina

Other Experience:

<u>Years:</u>	<u>Position:</u>	<u>Institution:</u>	<u>Dept:</u>
1993 - 1996	Physician Coordinator Hematology/Oncology Elective	The Medical Center of Central Massachusetts	Medicine
1996 - 1997	Block Coordinator Pathophysiology Neoplasia Section	University of Massachusetts Medical School	Pathology / Physiology

Membership in Professional/Scientific Societies:

National Societies:

1983 - 1991 American Medical Association
1988 - 1999 American College of Physicians
1994 - Present American Society of Clinical Oncology
1994 - 2005 American Society of Hematology
2001 - 2008 Best Doctors in America

Local Societies:

1983 - 1997 Massachusetts Medical Society
1983 - 1997 Worcester District Medical Society
1998 - Current South Carolina Medical Association

Honors:

2001 - 2006 Best Doctors in America, Best Doctors, Inc., Boston, MA

- | | |
|----------------|---|
| 2006 - Present | MUSC Trustees Leadership Academy, Medical University of South Carolina, Charleston, South Carolina |
| 2007 - Present | Advisory Board Physician Leadership Academy, Medical University of South Carolina, Charleston, South Carolina |

Editorial Positions:

Manuscript Reviewer for:

Journal of Clinical Oncology, Official Journal of the American Society of Clinical Oncology

Lung Cancer, Journal of the International Association for the Study of Lung Cancer

Journal Investigative Medicine, Journal of American Federal Medical Research

Academic Committee Activities:

College:

- | | |
|----------------|---|
| 1994 - 1996 | Blood Bank Committee, The Medical Center of Central Massachusetts, Worcester, Massachusetts |
| 1996 - 1997 | Protocol Review Committee, University of Massachusetts Medical Center, Worcester, Massachusetts |
| 1997 - 1999 | Clinical Research Committee, Medical University of South Carolina, Charleston, South Carolina |
| 1999 - 2002 | Pathology Review Committee, Medical University of South Carolina, Charleston, South Carolina |
| 2000 - 2001 | Vulnerable Population Committee, Medical University of South Carolina, Charleston, South Carolina |
| 2000 - Present | Hollings Cancer Center Clinical Trials Data and Safety Monitoring Board, Medical University of South Carolina, Charleston, South Carolina |
| 2000 - Present | Student Grade Appeals Committee, Medical University of South Carolina, Charleston, South Carolina |
| 2000 - 2002 | Chairman, Hollings Cancer Center Document Imaging Expansion Team, Medical University of South Carolina, Charleston, South Carolina |

2000 - 2002 Hollings Cancer Center New Building Project: Steering Committee, Clinic Committee, and Infusion Committee, Medical University of South Carolina, Charleston, South Carolina

2001 - 2002 Hollings Cancer Center New Building Project: Interiors Committee, Medical University of South Carolina, Charleston, South Carolina

2001 Chairman, Hollings Cancer Center Reimbursement Team, Medical University of South Carolina, Charleston, South Carolina

2001 - 2002 Hollings Cancer Center Clinical Strategic Planning Committee, Medical University of South Carolina, Charleston, South Carolina

2001 - 2003 Outreach Committee, Medical University of South Carolina, Charleston, South Carolina

2002 - 2006 Clinical Resource Value Committee, Medical University of South Carolina, Charleston, South Carolina

2002 - 2004 Clinical Council, Medical University of South Carolina, Charleston, South Carolina

2003 - 2007 Access Task Force of Clinical Council, Medical University of South Carolina, Charleston, South Carolina

2003 Chairman, Hollings Cancer Center Strategic Planning and Outreach Committee, Medical University of South Carolina, Charleston, South Carolina

2004 - 2007 Member, Hollings Cancer Center Clinical Affairs Council, Medical University of South Carolina, Charleston, South Carolina

2004 - 2008 Member, Hollings Cancer Center Executive Council, Medical University of South Carolina, Charleston, South Carolina

2004 - 2005 Search Committee, Chairman, Radiation Oncology, Medical University of South Carolina, Charleston, South Carolina

2004 - 2007 Search Committee, Chief, Hematology and Oncology Division, Medical University of South Carolina, Charleston, South Carolina.

2005 - 2006 Chairman, Sickle Cell Task Force, Medical University of South Carolina, Charleston, South Carolina.

2006 MUSC Excellence Physician Satisfaction Team, Medical University of South Carolina, Charleston, South Carolina

- 2006 - 2008 Practice Partner Physician Advisory Committee, Medical University of South Carolina, Charleston, South Carolina
- 2007 - Present Member, COEE in Tobacco Related Malignancy/Lung Cancer Center-Fundraising Committees
- 2007 - Present Member, COEE in Tobacco Related Malignancy/Lung Cancer Center-Recruitment Committee
- 2007 - Present Member, Hollings Cancer Center Clinical Council, Medical University of South Carolina, Charleston, South Carolina

Department:

- 1994 - 1996 Promotions Committee, The Medical Center of Central Massachusetts, Worcester, Massachusetts
- 1998 - 2002 Department of Medicine Compliance Committee, Medical University of South Carolina, Charleston, South Carolina
- 2007 - Present Member, Department of Medicine Peer Review Committee
- 2007 - Present Member, Department of Medicine Promotions & Tenure Committee

Division:

- 2000 - 2002 Oncology Cost Reduction Team, Medical University of South Carolina, Charleston, South Carolina

Major Teaching Responsibilities (Current):

Undergraduate Medical Education :

- 1997 - Present Instruction of medical students rotating on the Oncology Inpatient Service
- 1997 - Present Instruction of medical students rotating on the Oncology Consultation Service
- 2000 - Present Clinical Advisor for medical students
- 2001 - Present Preceptor for Physical Diagnosis Course, Second Semester

Graduate Medical Education:

- 1997 - Present Instruction of interns, residents, and fellows rotating on the Oncology Inpatient Service
- 1997 - Present Instruction of interns, residents, and fellows rotating on the Oncology Consultation Service
- 1997 - 2001 Instruction of Hematology/Oncology Fellows in Medical Oncology Clinic, Hollings Cancer Center
- 1997 - Present Instruction of Hematology/Oncology Fellows in Thoracic Multidisciplinary Clinic, Hollings Cancer Center
- 1997 - Present Participation in Hematology/Oncology Fellowship Training Conferences
- 1999 - Present Faculty Advisor for Hematology/Oncology Fellows

Continuing Medical Education:

- 2001 Program Co-Director, Oncology Update 2001, Charleston, South Carolina

Major Clinical Interests and Responsibilities:

Thoracic Malignancies:

Clinical responsibilities include providing all medical oncology services for patients seen at Thoracic Multidisciplinary Clinic, Hollings Cancer Center. Outpatient clinical activities include Five half-day clinics per week; thoracic malignancy patients constitute approximately 95% of patients seen.

Inpatient Responsibilities:

Inpatient clinical responsibilities include serving as Oncology Ward Attending two to three months per year. In addition to managing the inpatient service, this includes providing inpatient oncology consultations.

Clinical Research:

- 1997 - 1998 Co-Investigator, Phase I Trial of Gemcitabine and CP1-11 for Solid Tumors
- 1998 Principle Investigator, Phase I Study of Mitoguzone Dihydrochloride and Gemcitabine Administered Every Two Weeks in Patients with Advanced Cancer
- 1998 - 1999 Study Chair, CALGB 39805: 6-Hydroxymethylacylfulrene in the Treatment of Relapsed and Refractory Non-Small Cell Lung Cancer

1998 - 2000	Co-Investigator, Phase I Trial of Paclitaxel, Oral Topotecan and Oral Etoposide in Solid Tumors
1999 - 2000	Co-Investigator, Phase I Trial of Cisplatin, Gemcitabine and CPT-11 in Solid Tumors
1999 - 2000	Co-Investigator, Phase I Trial of Docetaxel, Gemcitabine and CPT-11 in Solid Tumors
2002 - 2007	Institutional Principle Investigator, A Phase III Study of Delayed vs. Immediate Second-Line Therapy with Docetaxel after Gemecitabine and Carboplatin in Advanced Non-Small Cell Lung Cancer
2003 - 2005	Institutional Principle Investigator, A Phase 2, Open-Label Study of MAC-321 Administered Intravenously as a Single Agent for the Treatment of Non-Small Cell Lung Cancer Refractory to Platinum-Based Therapy
2004 - 2007	Co-Investigator, Phase I Study of Topotecan in Combination with Vinorelbine in Recurrent Lung Cancer
2008	Co-Investigator, A Phase 2, Randomized, Multicenter, Open Label Study to Evaluate the Efficacy and Safety of Mapatumumab ([HGS1012], a Fully Human Monoclonal Antibody to Trail-R1) in Combination with Carboplatin and Paclitaxel as First Line Therapy in Subjects with Advanced Non-Small Cell Lung Cancer (NSCLC)
2008	Institutional Principle Investigator, A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Patients with Non-Small Cell Lung Carcinoma Who Are Progressing on Erlotinib
2008 - Present	Institutional Principle Investigator, A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared with Taxol and Carboplatin as First-line Therapy in Patients with Advanced Non-Small Cell Cancer (NSCLC)

Lectures and Presentations:

Invited Lectures and Presentations:

1990	Heparin-Induced Thrombocytopenia and Arterial Thrombosis, Medical Grand Rounds, The Medical Center of Central Massachusetts, Worcester, Massachusetts.
1993	Current Approaches in Cancer Therapy: A Case Management Seminar, Lymphoma Section Moderator, Worcester, Massachusetts.

- 1996 Overview of Lung Cancer, Symposium for Tumor Registrars, Worcester, Massachusetts.
- 1996 Chronic Myeloproliferative Disorders, Neoplasia Lecture Series, University of Massachusetts Medical School, Worcester, Massachusetts.
- 1996 Lung Cancer, Neoplasia Lecture Series, University of Massachusetts Medical School, Worcester, Massachusetts.
- 1999 6-Hydroxymethylacylfulvene in Relapsed and Refractory Non-Small Cell Lung Cancer, Symposium for Clinical Research Associates, Cancer and Leukemia Group B, Toronto, Canada.
- 1999 6-Hydroxymethylacylfulvene: Review of Toxicity, Presentation to the Respiratory Committee, Cancer and Leukemia Group B, Toronto, Canada.
- 2001 Small Cell Carcinoma of the Lung, Medical Grand Rounds, Medical University of South Carolina, Charleston, South Carolina.
- 2001 Small Cell Carcinoma of the Lung, Annual Meeting and Scientific Assembly of the South Carolina Medical Association, Charleston, South Carolina
- 2001 Small Cell Carcinoma of the Lung: Historical Perspective, Current Therapy and Future Directions, Oncology Update 2001, Charleston, South Carolina
- 2002 Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer, South Carolina Oncology Society Fall Membership Meeting, Charleston, South Carolina
- 2003 Locally Advanced Non-Small Cell Lung Cancer, South Carolina Lowcountry Oncology Nursing Society's Annual Spring Conference, Charleston, South Carolina

Community Service:

- 2001 Television Interview on Channel 5 News:
Lung Cancer: Prevention and Treatment

Publications:

Peer Reviewed Journal Articles:

1. Ip DP, **Arthur CD**, Winans RE, Appelman EH. Reaction of Fluoroxysulfate with Aromatic Compounds. *Journal of the American Chemical Society* 1981; 103:1964-1968.
2. Michelson AD, Gore JM, Rybak MD, **Cola CA**, Barnard MR. Effect of In Vivo Infusion of Recombinant Tissue-Type Plasminogen Activator on Platelet Glycoprotein Ib. *Thrombosis Research* 1990; 60:421-424.
3. **Cola C**, Ansell J. Heparin-Induced Thrombocytopenia and Arterial Thrombosis: Alternative Therapies. *American Heart Journal* 1990; 119, No. 2, Part I:368-374.
4. Leong SS, Rocha Lima CM, **Sherman CA**, Green MR. The 1997 International Staging System for Non-Small Cell Lung Cancer. Have All The Issues Been Addressed? *Chest* 1999; 115 (1):242-248.
5. Rocha Lima CM, Leong SS, **Sherman CA**, Perkel JA, Putman-Hair T, Safa AR, Green MR. Phase I Study of CPT-11 and Gemcitabine in Patients with Solid Tumors. *Cancer Therapeutics* 1999; 2:58-66.
6. Rocha Lima C, Eckardt J, Leong S, **Sherman C**, Perkel J, Putman-Hair T, Safa A, Bahadori H, Green M. Single Agent Gemcitabine and Gemcitabine-Irinotecan Combination (IriNoGem) in Non-Small Cell Lung Cancer. *Seminars in Oncology* 1999; 26(5) (Suppl 16):43-50.
7. Cappuzzo F, Rocha Lima CM, **Sherman CA**, Green MR. Advances in Treatment of Inoperable NSCLC: Gemcitabine Doublets C A Promising Alternative. *Oncology* 2000; 14(7) (Suppl 4):7-14.
8. Green MR, Rocha Lima CM, **Sherman CA**. Radiation and Chemotherapy for Patients with Stage III Non-Small Cell Lung Cancer. *Seminars in Rad Onc* 2000; 10(4):289-295.
9. **Sherman CA**, Rocha Lima CM, Turrisi AT, III. Limited Small-Cell Lung Cancer: A Potentially Curable Disease. *Oncology* 2000; 14(10):1395-1403.
10. Green MR, Harper M, Safa A, **Sherman CA**, Mushtaq CM, Bahadori H, Brescia FJ, Rocha Lima CM. Irinotecan in the Management of Patients with Pancreatic Carcinoma. *Oncology* 2000; 14(12) (Suppl 14):31-33.
11. Rocha Lima CM, Urbanic JJ, **Sherman CA**, Brescia FJ, Green MR. Docetaxel Followed by Gemcitabine and Irinotecan in Solid Tumors. *Oncology* 2001; 15(1) (Suppl 1):37-45.
12. Rocha Lima CM, **Sherman CA**, Brescia FJ, Brunson CY, Green MR. Irinotecan/Gemcitabine Combination Chemotherapy in Pancreatic Cancer. *Oncology* 2001; 15(3) (Suppl):46-51.
13. Turrisi AT, **Sherman CA**. The Treatment of Limited Small Cell Lung Cancer: A Report of Progress Made and Future Prospects. *European Journal of Cancer* 2002; 38:279-291.

14. Rocha Lima CM, Leong SS, **Sherman CA**, Perkel JA, Putman T, Safa AR, Green MR. Irinotecan and Gemcitabine in Patients with Solid Tumors: Phase I Trial. *Oncology* 2002; 16 (5) (suppl):19-24.
15. Silvestri GA, **Sherman C**, Williams T, Leong SS, Flume P, Turrisi A. Caring for the Dying Patient with Lung Cancer. *Chest* 2002; 122:1028-1036.
16. **Sherman CA**, Turrisi AT, Wallace MB, Reed CE. Locally Advanced Esophageal Cancer. Current Treatment Options in *Oncology* 2002; 3(6):475-485.
17. Akerly W, Herndon JE, Egorin MJ, Lyss AP, Kindler HL, Savarese DM, **Sherman CA**, Rosen DM, Hollis D, Ratain IMJ, Green MR. Weekly, High-Dose Paclitaxel in Advanced Lung Carcinoma: A Phase II Study with Pharmacokinetics by the Cancer and Leukemia Group B. *Cancer* 2003;97(10):2480-2486.
18. Frizzell Bart, Sinha D, Williams T, Reed CE, **Sherman CA**, Turrisi A. Influence of Celiac Axis Lymph Nodes in the Definitive Treatment of Esophageal Cancer. *American Journal of Clinical Oncology* 2003; 26(3):215-220.
19. Mitas M, Hoover L, Silvestri G, Reed C, Green M, Turrisi AT, **Sherman C**, Mikhitarian K, Cole DJ, Block MI, Gillanders WE. *Lunx* is a Superior Molecular Marker for Detection of Non-Small Cell Lung Cancer in Peripheral Blood. *Journal of Molecular Diagnostics* 2003; 5:237-242.
20. Turrisi A, Bogart J, **Sherman CA**, Silvestri G. The Role of Radiotherapy and Chemotherapy for Curative Management of Medically Inoperable and Stage III Non-Small Cell Lung Cancer, and Radiotherapy for Palliation of Symptomatic Disease. *Respiratory Care Clinics of North America* 2003; 9: (2): 163-190.
21. Rocha Lima CM, Catapano CV, Pacheco D, **Sherman CA**, Oakhill G, Mushtaq C, Freeman KD, Green MR. A Phase I Study of Sequential Administration of Escalating Doses of Intravenous Paclitaxel, Oral Topotecan, and Fixed-Dose Oral Etoposide in Patients with Solid Tumors. *Cancer* 2004; 100: 2671-2679.
22. **Sherman CA**, Herndon JE 2nd, Watson DM, Green MR. A Phase II Trial of 6-Hydroxymethylacylfulvene (MGI -114, irofulven) in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer. *Lung Cancer* 2004; 45:387-392.
23. Urbanic JJ, Turissi AT, Sharma AK, Silvestri GA, Williams TE, Vanek KN, **Sherman CA**. Conformal High-Dose External Radiation Therapy(CHERT), 80.5 Gy, Alone for Medically Inoperable Non-Small Cell Lung Cancer(MILC) – A Retrospective Analysis. *Journal of Thoracic Oncology*. 2006;1: 112-119
24. Beldner MA, **Sherman CA**, Green MR, Garrett-Mayer E, Chaudhary U, Meyer M, Kraft AS and Montero AJ. Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. *BMC Cancer*. 2007, 7:231

25. Watkins JM, Wahlquist AE, Shirai K, Garrett-Mayer E, Aguero EG, Fortney JA, **Sherman CA**, Sharma AK. Factors associated with severe acute esophagitis from hyperfractionated radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer. [In Press] Manuscript accepted for publication in *Int J Radiat Oncol Biol Phys*, 1 Oct 2008; available online 10 Dec 2008.
26. Ruppert BN, Watkins JM, Shirai K, Wahlquist AE, Aguero EG, **Sherman CA**, Reed CE, Sharma AK. Concurrent chemoradiotherapy with cisplatin/irinotecan versus carboplatin/paclitaxel for loco-regionally advanced esophageal cancer. [In Press] Manuscript accepted for publication in *Am J Clin Oncol*, 27 Feb 2009.
27. Watkins JM, Fortney JA, Wahlquist AH, Shirai K, Garrett-Mayer E, Aguero EG, **Sherman CA**, Turrisi AT, Sharma AK. Once-daily radiotherapy to ≥ 59.4 Gy versus twice-daily radiotherapy to ≥ 45 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomes. [Under Review] Manuscript submitted to *Lung Cancer*, 22 Feb 2009.

Chapters in Scholarly Books:

1. **Cola C**, Ansell J. Platelet-Mediated Bleeding Disorders. In: Rakel R, ed. *Conn=s Current Therapy*. Philadelphia: WB Saunders, 1990.
2. **Cola C**, Ansell J. Autoimmune Hemolytic Anemia. In: Rakel R, ed. *Conn=s Current Therapy*. Philadelphia: WB Saunders, 1991.
3. Turrisi, AT, III, **Sherman, CA**. The Treatment of Limited Small Cell Lung Cancer: Progress and Future Promise. In: Detterbeck FC, Rivera MP, Socinski MA, Rosenman JG, ed. *Diagnosis and Treatment of Lung Cancer, Updates*. W.B. Saunders, 2001; 2(2):1-14.
4. Shirai, Keisuke, **Sherman, CA**. Chemotherapy for Lung Cancer. In: Ravenel James G, ed. *Lung Cancer Imaging*. Totowa New Jersey: Humana Press, 2007

Other Publications:

Abstracts:

1. Michelson AD, Barnard MR, Ryback ME, Gore JM, **Cola CA**. In Vivo Infusion of Recombinant Tissue-Type Plasminogen Activator Results in a Redistribution of Platelet Glycoprotein Ib Stores. *Circulation Supplement* 1988; 78: II-620.
2. Rocha Lima C, Perkel J, Putman-Hair T, **Sherman CA**, Leong S, Green MR. Ongoing Phase I Study of Irinotecan (CPT-11) and Gemcitabine (GEM). *Proc. Am. Soc. Clin. Onc.* 1998; 17:A961.

3. Akerley W, Herndon J, Egorin MJ, Lyss A, Kindler H, Savarese D, **Sherman CA**, Rosen MD, Ratain M, Green MR, Cancer and Leukemia Group B, Chicago, IL. CALGB 9731: Phase II Trial of Weekly Paclitaxel for Advanced Non-Small Cell Lung Cancer (NSCLC). *Proceedings of ASCO* 1999; 18:462A.
4. Rocha Lima C, **Sherman CA**, Brescia F, et. al. Phase II Trial of Gemcitabine and CPT-11 in Previously Untreated, Advanced and Metastatic Pancreas Cancer. *First Young Investigator Meeting* 1999; 1:14.
5. Rocha Lima C, **Sherman C**, Mushtaq C, Harper M, Catapano C, Pacheco D, Lightcap K, Garden D, Green M. Phase I Trial of Paclitaxel, Oral Topotecan and Oral Etoposide in Solid Tumors. *Lung Cancer* 1999; 25:238-239.
6. Rocha Lima CS, Catapano CV, **Sherman CA**, et. al. Phase I Trial of Docetaxel (D), Gemcitabine (G), and Irinotecan (I) in Patients with Solid Tumors. *Proc AACR* 2000; 41:A3872.
7. Green JL, Page GP, Reed CE, **Sherman CA**, Rocha Lima CM, Silvestri G, Roest J, Shealy KM, Griffin BC, Jones E, Green MR. High Risk Lung Cancer Registry Experience at Medical University of South Carolina. *Proc ASCO* 2000; 19:A1990.
8. **Sherman CA**, Herndon J, II, Green MR; Cancer and Leukemia Group B, Chicago, IL. CALGB 39805: Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients with Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC). *Proc ASCO* 2000; 19:A2163.
9. Beldner M, Montero AJ, **Sherman CA**; A Phase I Study of Weekly Topotecan and Vinorelbine in Recurrent Lung Cancer. *Proc ASCO* 2006; 24:17140.
10. Fortney JA, Watkins JM, Shirai KS, Herrin AE, **Sherman C**, Aguero EG, Garrett-Mayer E, Sharma AK. Survival comparison of dose-optimized once versus twice-daily radiotherapy with concurrent chemotherapy for limited stage small-cell lung cancer. Poster Presentation at the 90th Annual Meeting of the American Radium Society, Laguna Niguel, California: 3 May 2008.
11. Watkins JM, Herrin AE, Shirai KS, Garrett-Mayer E, Aguero EG, **Sherman CA**, Sharma AK. Impact of treatment duration and delays on in-field disease control for twice-daily radiotherapy (BID-RT) in limited-stage small-cell lung cancer (SCLC). [Abstract accepted for poster discussion at the 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Boston, MA: 23 Sept 2008.]
12. Shirai K, Watkins JM, Herrin AE, Garrett-Mayer E, Aguero EG, **Sherman CA**, Sharma AK. Impact of treatment duration and delays on in-field disease control for twice-daily radiotherapy (BID-RT) in limited-stage small-cell lung cancer (SCLC). *Int J Radiat Oncol Biol Phys* 2008;72(suppl 1):S116-S117.
13. Fortney JA, Watkins JM, Herrin AE, Shirai KS, **Sherman CA**, Garrett-Mayer E, Aguero EG, Sharma AK. Limited-stage small-cell lung cancer: dose-optimized comparison of

twice- versus once-daily radiotherapy with concurrent chemotherapy. [Abstract]
Oncology 2008;22(suppl 1):55-56

14. Watkins JM, Herrin AE, Shirai KS, Garrett-Mayer E, Agüero EG, Fortney JA, **Sherman CA**, Sharma AK. Predictors of severe esophagitis from twice-daily thoracic radiotherapy and concurrent chemotherapy for small-cell lung cancer. [Abstract]
Oncology 2008;22(suppl 1):15-16.